Abstracts tagged "Biologicals"

Abstract Number: 0391 • ACR Convergence 2022
Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
William Tillett¹, Alexander Egeberg², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Nail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed…
Abstract Number: 0542 • ACR Convergence 2022
ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update
Sofia Ramiro¹, Elena Nikiphorou², Alexandre Sepriano³, Augusta Ortolan⁴, Casper Webers⁵, Xenofon Baraliakos⁶, Robert Landewé⁷, Filip Van den bosch⁸, Boryana Boteva⁹, Ann Bremander¹⁰, Philippe Carron¹¹, Adrian Ciurea¹², floris van Gaalen¹, Pal Geher¹³, Lianne Gensler¹⁴, Josef Hermann¹⁵, Manouk de Hooge¹⁶, Marketa Husakova¹⁷, Uta Kiltz¹⁸, Clementina Lopez-Medina¹⁹, Pedro Machado²⁰, Helena Marzo-Ortega²¹, Anna Molto²², Victoria Navarro-Compán²³, Michael Nissen²⁴, Fernando Pimentel-Santos²⁵, Denis Poddubnyy²⁶, Fabian Proft²⁶, Martin Rudwaleit²⁷, Mark Telkman⁹, Sizheng Zhao²⁸, Nelly Ziade²⁹ and Désirée van der Heijde³⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center & King's College London, London, United Kingdom, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴University of Padova/Leiden University Medical Center, Padova, Italy, ⁵Maastricht University Medical Centre, Maastricht, Netherlands, ⁶Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁷Amsterdam University Medical Center, Meerssen, Netherlands, ⁸Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁹Patients with Arthritis and Rheumatism (PARE) working group, EULAR, Zürich, Switzerland, ¹⁰Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark, ¹¹Ghent University Hospital, Ghent, Belgium, ¹²University Hospital Zurich, Zürich, Switzerland, ¹³Semmelweis University, Budapest, Hungary, ¹⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ¹⁵Medical University of Graz, Graz, Austria, ¹⁶Ghent University Hospital, Luxembourg, Luxembourg, ¹⁷Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Prague, Czech Republic, ¹⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ¹⁹Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ²⁰University College London, London, United Kingdom, ²¹Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ²²Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France, ²³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²⁴Hopitaux Universitaires de Genève, Geneva, Switzerland, ²⁵NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, ²⁶Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ²⁸University of Manchester, Liverpool, United Kingdom, ²⁹Saint-Joseph University, Beirut, Lebanon, ³⁰Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Since the last update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) in 2016, substantial new evidence has become available on…
Abstract Number: 0808 • ACR Convergence 2022
Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital
Cristobal Pavez Perales¹, Alba Torrat Novés², José Ivorra Cortés¹, Samuel Leal Rodriguez¹, Anderson V Huaylla Quispe³, Carmen Riesco Bárcena², Laura Mas Sanchez¹, Pablo Muñoz Martinez⁴, Elena Grau García¹, Elvira Vicens Bernabeu¹, José Eloy Oller Rodrígez¹, Francisco Miguel Ortiz Sanjuan⁵, Isabel Martínez-Cordellat¹, Rosa Negueroles Albuixech¹, Berta Lopez Montecinos⁶, Carmen Nájera Herranz¹, Inés Cánovas Olmos¹, Daniel Ramos Castro¹, Inmaculada Calvo Penades⁷, Luis González Puig⁸ and José andrés Román ivorra⁹, ¹Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ²Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ³Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ⁴Rheumatology Department. Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, Spain, Spain, ⁶Pediatric Rheumatology Unit. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ⁷Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain, ⁸Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain, ⁹Hospital Universitari i Politécnic la Fe, València, Spain
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the leading cause of chronic inflammatory rheumatic disease in children. It's classified into subtypes with different relative prevalences depending…
Abstract Number: 0974 • ACR Convergence 2022
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Lucy Marie Carter¹, Zoe Wigston¹, Jack Arnold¹ and Philip Laws², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype…
Abstract Number: 1075 • ACR Convergence 2022
Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Jane Bentley⁴, Jonathan Steinfeld⁵, Steven Yancey⁶, Namhee Kwon⁷, Praveen Akuthota⁸, Paneez Khoury⁹, Lee Baylis¹⁰ and Michael Wechsler¹¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵Clinical Sciences, Respiratory, GSK (affiliation at time of research), Philadelphia, PA, ⁶Respiratory Therapeutic Area, GSK (affiliation at the time of research), Research Triangle Park, NC, ⁷Clinical Sciences, Respiratory, GSK, Brentford, United Kingdom, ⁸Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, ⁹Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Global Medical Affairs, GlaxoSmithKline, Durham, NC, ¹¹Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) can have vasculitic or eosinophilic phenotypes. The MIRRA study demonstrated that patients with EGPA spent more time…
Abstract Number: 1427 • ACR Convergence 2022
Impact of Upadacitinib versus Abatacept on Individual Disease Outcomes in Patients with Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs
Ronald van Vollenhoven¹, Andrea Rubbert-Roth², Stephen Hall³, Ricardo Xavier⁴, Anna K Shmagel⁵, Yanna Song⁵, Samuel Anyanwu⁵ and Vibeke Strand⁶, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ³Emeritus Research and Monash University, Melbourne, Australia, ⁴Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁵AbbVie, Inc., North Chicago, IL, ⁶Stanford University School of Medicine, Stanford, CA
Background/Purpose: The phase 3 SELECT-CHOICE trial of patients with rheumatoid arthritis (RA) and prior inadequate response to biologic DMARD(s) (bDMARD-IR) demonstrated superiority of the JAK…
Abstract Number: 1652 • ACR Convergence 2022
Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
Kenneth C. Kalunian¹, Richard A. Furie², Eric F. Morand³, Ian N. Bruce⁴, Susan Manzi⁵, Yoshiya Tanaka⁶, Kevin Winthrop⁷, Gabriel Abreu⁸, Ihor Hupka⁹, Lijin Zhang¹⁰, Shanti Werther¹¹, Micki Hultquist¹², Raj Tummala¹⁰ and Catharina Lindholm¹¹, ¹UC San Diego, La Jolla, CA, ²Northwell Health, Great Neck, NY, ³Monash University, Melbourne, Australia, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Oregon Health & Science University, Portland, OR, ⁸AstraZeneca, Mölndal, Sweden, ⁹AstraZeneca, Warsaw, Poland, ¹⁰AstraZeneca, Gaithersburg, MD, ¹¹AstraZeneca, Gothenburg, Sweden, ¹²AstraZeneca, Bethesda, MD
Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody that binds to the type I IFN receptor and inhibits type I IFN signaling.1 In…
Abstract Number: 2056 • ACR Convergence 2022
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Takehiro Nakai¹, Sho Fukui², Takahiro Asano³, Futoshi Iwata⁴, Hiroki Ozawa⁵, Satoshi Kawaai⁴, Yukihiko Ikeda¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁶, Kenichi YAMAGUCHI⁷ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Kyorin University Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo City Tokyo, Japan, ⁴St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
Abstract Number: 2152 • ACR Convergence 2022
Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis
Nicoletta Luciano¹, Elisa Barone², Enrico Brunetta¹, Maria De Santis³, Angela Ceribelli⁴, Marta Caprioli⁵, Giacomo Maria Guidelli¹, Arianna Sonaglia¹, Daniela Renna⁶, Francesca Motta⁷, Natasa Isailovic⁷, Matteo Vecellio³ and Carlo Selmi⁸, ¹IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ²IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano (MI), Lombardia, Italy, ³Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Milano, Italy, ⁷Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano (MI), Italy, ⁸Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy
Background/Purpose: The management of patients with psoriasis and psoriatic artrhitis (PsA) has been recently enriched and has thus become more challenging by the wide armamentarium…
Abstract Number: 0078 • ACR Convergence 2022
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems
Alexis Ogdie¹, Marina Magrey², Robert Fitzsimmons³, Shahrzad Abdollahi⁴, Wai Chung Yong⁵, Yasir Tarabichi⁶, Ana Biljan⁷, Christopher D. Saffore⁷, Kristin Tacelosky⁷ and Jessica Walsh⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Case Western Reserve University, University Hospitals, Richfield, OH, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA, ⁵Division of Rheumatology, The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, ⁶Department of Clinical Informatics Research and Education, The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, ⁷AbbVie, Inc., North Chicago, IL, ⁸University of Utah, Salt Lake City, UT
Background/Purpose: Most patients with undiagnosed ankylosing spondylitis (AS) seek care for back pain from primary care providers (PCPs), and treatment strategies adopted by PCPs may…
Abstract Number: 0302 • ACR Convergence 2022
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
SE RIM CHOI¹, Anna Shin², You-Jung Ha², Yun Jong Lee², Eun Bong Lee¹ and Eun Ha Kang², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Background/Purpose: To compare infectious risk between JAK inhibitors (JAKi) versus TNF inhibitors (TNFi) among patients with rheumatoid arthritis (RA) in Korea. Methods: Using 2009-2019 Korea…
Abstract Number: 0403 • ACR Convergence 2022
Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
Yu Xue¹, Jiankang Hu², Dongzhou Liu³, Jingyang Li⁴, Huaxiang Wu⁵, Chunyu Tan⁶, Lie Dai⁷, Mengru Liu⁸, Hongying Li⁸ and Hejian Zou¹, ¹Huashan Hospital affiliated to Fudan University, Shanghai, China, ²Jiangxi Pingxiang People’s Hospital, Shanghai, China, ³Shenzhen People’s Hospital （The Second Clinical Medical College of Jinan University）, Shanghai, China, ⁴Zhuzhou Central Hospital, Shanghai, China, ⁵The Second Affiliated Hospital Zhejiang University School of Medicine, Shanghai, China, ⁶West China Hospital of Sichuan University, Shanghai, China, ⁷Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Shanghai, China, ⁸Eli Lilly and Company, Shanghai, China
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in global clinical trials in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis…
Abstract Number: 0547 • ACR Convergence 2022
Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers
Nicolas Rosine¹, Surya Koturan¹, Vincent Guillemot², Claire Leloup¹, Fanni Veress¹, Tharshana Stephen¹, Hanan Yahia-Cherbal¹, Jérémie SELLAM³, Francis Berenbaum⁴, Natalia Pietrosemoli¹, Elisabetta Bianchi¹, Corinne MIceli⁵ and Lars Rogge¹, ¹Institut Pasteur, Paris, France, ²Institut Pasteur, Paris, Ile-de-France, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁴Sorbonne University - Saint-Antoine hospital, Paris, France, ⁵APHP, Paris, France
Background/Purpose: IL-17A inhibitors (IL-17i) and TNF-inhibitors (TNFi) are currently the only biologic drugs available to treat axial spondyloarthritis (axSpA). While several studies have provided mechanistic…
Abstract Number: 0809 • ACR Convergence 2022
Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira and AVT02
Kathleen Richter¹, Halimuniyazi Haliduola¹, Jana Schockaert², Aurélie Mazy³, Nataliya Reznichenko⁴, Eric Guenzi⁵ and Fausto Berti⁶, ¹Alvotech, Jülich, Germany, ²ImmunXpert, Ghent, Belgium, ³ImmunXpert, Charleroi, Belgium, ⁴Military Hospital (Military Unit A3309) of Military-Medical Clinical Center of Southern Region, Zaporizhzhia, Ukraine, ⁵UGA Biopharma, Bonn, Germany, ⁶Alvotech, Zürich, Switzerland
Background/Purpose: A common reason for clinical development failure of biologic medicines is immunogenicity. Immunogenicity is traditionally measured by detecting neutralizing (NAb) anti-drug antibodies (ADA) in…
Abstract Number: 0976 • ACR Convergence 2022
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Alvaro Gomez¹, Sandra Jägerback¹, Christopher Sjöwall² and Ioannis Parodis³, ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Renal flares contribute substantially to morbidity, renal survival and death in systemic lupus erythematosus (SLE). Identification of pharmacological strategies for the prevention of renal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].